ATAI LIFE SCIENCES NV (ATAI)
NL0015000DX5 - Common Stock
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Stay updated with the stocks that are on the move in today's after-hours session.
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Q3 2024 earnings ...
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ATAI Life Sciences (NASDAQ:ATAI) just reported results for the second quarter o...
ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
ATAI stock results show that ATAI Life Sciences missed analyst estimates for earnings per share the second quarter of 2024.
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
atai Reports Q2 2024 Financial Results and Corporate Updates...
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference in August 2024...
3 Dirt-Cheap Drug Developers With Blockbuster Potential
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases.
3 Psychedelic Stocks to Ride to the Moon and Beyond
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the cannabis industry has all but become legitimate in the United States,...
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent,...